Drug development

Kither Biotech is focused on developing novel inhaled therapies targeting intracellular signaling pathways involved in respiratory diseases with high unmet medical need, including chronic obstructive pulmonary disease (COPD), non-cystic fibrosis bronchiectasis (NCFBE), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis (CF).

The company’s approach is based on localized modulation of disease-relevant pathways directly within the lungs, aiming to maximize its therapeutic effects in the lung while minimizing systemic exposure. Kither has developed a proprietary pipeline of inhaled compounds targeting PI3K-dependent signaling mechanisms involved in inflammation, airway obstruction, impaired mucociliary clearance, and fibrotic remodeling.